“An Ounce of Prevention…”
This article relates to:
-
Prophylactic Use of Cardiac Medications and Survival in Duchenne Muscular Dystrophy
- Kristin M. Conway,
- Shiny Thomas,
- Tahereh Neyaz,
- Emma Ciafaloni,
- Joshua R. Mann,
- Michelle Staron-Ehlinger,
- Gary S. Beasley,
- Paul A. Romitti,
- Katherine D. Mathews,
- the Muscular Dystrophy Surveillance, Tracking and Research Network (MD STARnet),
- Volume 71Issue 4Muscle & Nerve
- pages: 574-582
- First Published online: January 24, 2025
Eleanor Greiner
Heart Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
Contribution: Conceptualization, Writing - original draft, Writing - review & editing
Search for more papers by this authorCorresponding Author
Chet R. Villa
Heart Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
Correspondence:
Chet R. Villa ([email protected])
Contribution: Conceptualization, Writing - original draft, Writing - review & editing
Search for more papers by this authorEleanor Greiner
Heart Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
Contribution: Conceptualization, Writing - original draft, Writing - review & editing
Search for more papers by this authorCorresponding Author
Chet R. Villa
Heart Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
Correspondence:
Chet R. Villa ([email protected])
Contribution: Conceptualization, Writing - original draft, Writing - review & editing
Search for more papers by this authorConflicts of Interest
C.R.V. has received support from, and/or has served as a paid consultant for PTC Therapeutics, Pfizer, Sarepta, Capricor, Antisense, Solid Bioscience, Fibrogen, and Edgewise. He has also received funding from Parent Project Muscular Dystrophy. E.G. declares no conflicts of interest.
Open Research
Data Availability Statement
Data sharing not applicable-no new data generated.
References
- 1L. Passamano, A. Taglia, A. Palladino, et al., “Improvement of Survival in Duchenne Muscular Dystrophy: Retrospective Analysis of 835 Patients,” Acta Myologica 31, no. 2 (2012): 121–125, https://www.ncbi.nlm.nih.gov/pubmed/23097603.
- 2L. Wahlgren, A. K. Kroksmark, M. Tulinius, and K. Sofou, “One in Five Patients With Duchenne Muscular Dystrophy Dies From Other Causes Than Cardiac or Respiratory Failure,” European Journal of Epidemiology 37, no. 2 (2022): 147–156, https://doi.org/10.1007/s10654-021-00819-4.
- 3C. Villa, S. R. Auerbach, N. Bansal, et al., “Current Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD): Understanding Care Practices in Order to Optimize DMD Heart Failure Through ACTION,” Pediatric Cardiology 43, no. 5 (2022): 977–985, https://doi.org/10.1007/s00246-021-02807-7.
- 4C. Spurney, R. Shimizu, L. P. Morgenroth, et al., “Cooperative International Neuromuscular Research Group Duchenne Natural History Study Demonstrates Insufficient Diagnosis and Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy,” Muscle & Nerve 50, no. 2 (2014): 250–256, https://doi.org/10.1002/mus.24163.
- 5C. A. Wittlieb-Weber, K. R. Knecht, C. R. Villa, et al., “Risk Factors for Cardiac and Non-Cardiac Causes of Death in Males With Duchenne Muscular Dystrophy,” Pediatric Cardiology 41, no. 4 (2020): 764–771, https://doi.org/10.1007/s00246-020-02309-y.
- 6D. J. Birnkrant, K. Bushby, C. M. Bann, et al., “Diagnosis and Management of Duchenne Muscular Dystrophy, Part 2: Respiratory, Cardiac, Bone Health, and Orthopaedic Management,” Lancet Neurology 17, no. 4 (2018): 347–361, https://doi.org/10.1016/S1474-4422(18)30025-5.
- 7B. Feingold, W. T. Mahle, S. Auerbach, et al., “Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association,” Circulation 136, no. 13 (2017): e200–e231, https://doi.org/10.1161/CIR.0000000000000526.
- 8M. C. Silva, T. A. Magalhaes, Z. M. Meira, et al., “Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial,” JAMA Cardiology 2, no. 2 (2017): 190–199, https://doi.org/10.1001/jamacardio.2016.4801.
- 9D. Duboc, C. Meune, G. Lerebours, J. Y. Devaux, G. Vaksmann, and H. M. Becane, “Effect of Perindopril on the Onset and Progression of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy,” Journal of the American College of Cardiology 45, no. 6 (2005): 855–857, https://doi.org/10.1016/j.jacc.2004.09.078.
- 10R. Porcher, I. Desguerre, H. Amthor, et al., “Association Between Prophylactic Angiotensin-Converting Enzyme Inhibitors and Overall Survival in Duchenne Muscular Dystrophy-Analysis of Registry Data,” European Heart Journal 42, no. 20 (2021): 1976–1984, https://doi.org/10.1093/eurheartj/ehab054.
- 11H. D. Allen, K. M. Flanigan, P. T. Thrush, et al., “A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy,” PLoS Currents 5 (2013): ea865, https://doi.org/10.1371/currents.md.2cc69a1dae4be7dfe2bcb420024ea865.
10.1371/currents.md.2cc69a1dae4be7dfe2bcb420024ea865 Google Scholar
- 12K. M. Conway, S. Thomas, T. Neyaz, et al., “Prophylactic Use of Cardiac Medications and Survival in Duchenne Muscular Dystrophy,” Muscle & Nerve 71, no. 4 (2025): 574–582.
- 13A. Breaux, S. M. Lang, S. Wittekind, et al., “Cardiac Histopathology in Duchenne Muscular Dystrophy Demonstrates Diffuse Fibrofatty Replacement of the Myocardium,” Journal of the American Heart Association 13, no. 22 (2024): e033862, https://doi.org/10.1161/jaha.123.033862.
- 14S. D. Sunthankar, K. George-Durrett, K. Crum, et al., “Comprehensive Cardiac Magnetic Resonance T1, T2, and Extracellular Volume Mapping to Define Duchenne Cardiomyopathy,” Journal of Cardiovascular Magnetic Resonance 25, no. 1 (2023): 44, https://doi.org/10.1186/s12968-023-00951-y.
- 15W. D. Rooney, Y. A. Berlow, W. T. Triplett, et al., “Modeling Disease Trajectory in Duchenne Muscular Dystrophy,” Neurology 94, no. 15 (2020): e1622–e1633, https://doi.org/10.1212/WNL.0000000000009244.
- 16K. N. Hor, M. D. Taylor, H. R. Al-Khalidi, et al., “Prevalence and Distribution of Late Gadolinium Enhancement in a Large Population of Patients With Duchenne Muscular Dystrophy: Effect of Age and Left Ventricular Systolic Function,” Journal of Cardiovascular Magnetic Resonance 15, no. 1 (2013): 107, https://doi.org/10.1186/1532-429X-15-107.
- 17J. G. Andrews, K. Conway, C. Westfield, et al., “Implementation of Duchenne Muscular Dystrophy Care Considerations,” Pediatrics 142, no. 1 (2018): e20174006, https://doi.org/10.1542/peds.2017-4006.
- 18L. Cowen, M. Mancini, A. Martin, A. Lucas, and J. M. Donovan, “Variability and Trends in Corticosteroid Use by Male United States Participants With Duchenne Muscular Dystrophy in the Duchenne Registry,” BMC Neurology 19, no. 1 (2019): 84, https://doi.org/10.1186/s12883-019-1304-8.
- 19H. Patolia, M. S. Khan, G. C. Fonarow, J. Butler, and S. J. Greene, “Implementing Guideline-Directed Medical Therapy for Heart Failure: JACC Focus Seminar 1/3,” Journal of the American College of Cardiology 82, no. 6 (2023): 529–543, https://doi.org/10.1016/j.jacc.2023.03.430.
